--- title: "Multivariate analysis of factors associated with persistent colesevela | Sutter Health" description: "This study identified several patient demographic and characteristics associated with persistent colesevelam treatment that may help develop strategies to improve treatment persistence and optimize clinical outcomes." url: "https://www.sutterhealth.org/research/publications/factors-associated-with-persistent-colesevelam-tx-1055312600" --- 1. [Home](https://www.sutterhealth.org/) / 2. [Research](https://www.sutterhealth.org/research) / 3. [Research publications](https://www.sutterhealth.org/research/publications) / 4. Multivariate analysis of factors associated with persistent colesevela # Multivariate analysis of factors associated with persistent colesevelam treatment among patients with hypercholesterolemia. Romanelli RJ, Leahy A, Jukes T, Ye X, Kang A, & Ishisaka DY. _Ann Pharmacother. 47(10):1247-52. doi: 10.1177/1060028013501804._ 2013-10-01 ## Abstract #### BACKGROUND: Persistent treatment with lipid-lowering therapies is important for achieving optimal clinical outcomes. To date, no study has evaluated the real-world use of colesevelam and the factors associated with persistent colesevelam treatment. #### OBJECTIVE: The primary objective of this study was to examine patient demographic and characteristics associated with persistent colesevelam treatment in real-world clinical practice. #### METHODS: In this retrospective cohort study, adult patients with hypercholesterolemia, an initial order for colesevelam between January 2004 and December 2011, a low-density lipoprotein cholesterol (LDL-C) value ≤ 3 months from the initial order date (baseline), and ≥ 12 months of follow-up were identified through electronic health records. Persistent treatment was defined as no medication order gap >30 days during a 12-month period. Multivariate logistic regression was performed to assess factors associated with persistent treatment. Odds ratios (ORs) and 95% confidence intervals (CIs) were calculated. A P value <.05 was considered statistically significant. #### RESULTS: A total of 971 patients met eligibility criteria. Forty-nine percent of patients had ≥ 12 months of persistent treatment. Multivariate analysis showed that female sex (OR = 0.69; 95% CI = 0.53, 0.90; P = .004) was associated with lesser odds of persistence, whereas baseline LDL-C at goal (1.39; 1.06, 1.82; P = .015) and concomitant use of the intestinal cholesterol absorption inhibitor ezetimibe (1.64; 1.18, 2.28; P = .003) were associated with greater odds of persistence. #### CONCLUSIONS: This study identified several patient demographic and characteristics associated with persistent colesevelam treatment that may help develop strategies to improve treatment persistence and optimize clinical outcomes. [PubMed abstract](http://www.ncbi.nlm.nih.gov/pubmed/24259687) ## Research topics - [Cardiovascular Diseases](https://www.sutterhealth.org/research-search-results?query=%22%5C%22Cardiovascular+Diseases%5C%22%22) - [Disease Management](https://www.sutterhealth.org/research-search-results?query=%22%5C%22Disease+Management%5C%22%22) - [Health Services](https://www.sutterhealth.org/research-search-results?query=%22%5C%22Health+Services%5C%22%22) ## Related publications [View all publications](https://www.sutterhealth.org/research-search-results?verticalKey=research_publication) - Publication ### [Compliance after switching from branded to generic statins.](https://www.sutterhealth.org/research/publications/compliance-switch-from-branded-to-generic-statins-1055312703) Romanelli RJ, Jukes T, Segal JB. Pharmacoepidemiol Drug Saf. doi: 10.1002/pds.3630. 2014 May 09 - Publication ### [Predictors of statin compliance after switching from branded to generic agents among managed-care beneficiaries.](https://www.sutterhealth.org/research/publications/statin-compliance-predictors-branded-to-generic-1055312734) Romanelli RJ, Segal JB. J Gen Intern Med. \[Epub ahead of print\] 2014 Jun 24 - Publication ### [Financial incentives and cholesterol levels.](https://www.sutterhealth.org/research/publications/financial-incentives-and-cholesterol-levels-1055312411) Lesser LI, McCormack JP. JAMA. 315(15):1657-8. doi: 10.1001/jama.2016.0309. 2016 Apr 19 - Publication ### [Improving adherence to best-practice guidelines for venous thromboembolism risk assessment and prevention.](https://www.sutterhealth.org/research/publications/improving-adherence-to-best-practice-in-vte-1055312724) Schiro TA, Sakowski J, Romanelli RJ, Jukes T, Newman J, Hudnut A, Leonard T. Am J Health Syst Pharm. 68(22):2184-9. doi: 10.2146/ajhp110102. 2011 Nov 15 - Publication ### [Colesevelam in the treatment of hypercholesterolemia and hyperglycemia: a retrospective analysis from an ambulatory care medical network.](https://www.sutterhealth.org/research/publications/colesevelam-in-treatment-of-hypercholesterolemia-1055312718) Romanelli RJ, Leahy A, Jukes T, Ye X, Qian C, Ishisaka DY. Curr Med Res Opin. 29(12):1747-56. doi: 10.1185/03007995.2013. 2013 Dec 01 [View all publications](https://www.sutterhealth.org/research-search-results?verticalKey=research_publication) ```json {"@context":"https://schema.org","@type":"MedicalOrganization","name":"Sutter Health","@id":"https://www.sutterhealth.org/#medicalorganization","url":"https://www.sutterhealth.org","logo":"https://www.sutterhealth.org/static/images/sutter-health-logo.svg","address":{"@type":"PostalAddress","streetAddress":"2200 River Plaza Drive","addressLocality":"Sacramento","addressRegion":"CA","postalCode":"95833","addressCountry":"US"},"areaServed":{"@type":"AdministrativeArea","name":"California"},"sameAs":["https://www.facebook.com/SutterHealth","https://www.instagram.com/sutterhealth/","https://x.com/SutterHealth","https://www.youtube.com/sutterhealth","https://www.linkedin.com/company/sutter-health","https://en.wikipedia.org/wiki/Sutter_Health"]} ``` ```json {"@context":"https://schema.org","@type":"BreadcrumbList","@id":"https://www.sutterhealth.org/research/publications/factors-associated-with-persistent-colesevelam-tx-1055312600#breadcrumblist","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https://www.sutterhealth.org/"},{"@type":"ListItem","position":2,"name":"Research","item":"https://www.sutterhealth.org/research"},{"@type":"ListItem","position":3,"name":"Research publications","item":"https://www.sutterhealth.org/research/publications"},{"@type":"ListItem","position":4,"name":"Multivariate analysis of factors associated with persistent colesevela"}]} ``` ```json {"@context":"https://schema.org","@type":"MedicalScholarlyArticle","@id":"https://www.sutterhealth.org/research/publications/factors-associated-with-persistent-colesevelam-tx-1055312600#medicalscholarlyarticle","name":"Multivariate analysis of factors associated with persistent colesevelam treatment among patients with hypercholesterolemia.","headline":"Multivariate analysis of factors associated with persistent colesevela","abstract":"BACKGROUND: Persistent treatment with lipid-lowering therapies is important for achieving optimal clinical outcomes. To date, no study has evaluated the real-world use of colesevelam and the factors associated with persistent colesevelam treatment. OBJECTIVE: The primary objective of this study was to examine patient demographic and characteristics associated with persistent colesevelam treatment in real-world clinical practice. METHODS: In this retrospective cohort study, adult patients with hypercholesterolemia, an initial order for colesevelam between January 2004 and December 2011, a low-density lipoprotein cholesterol (LDL-C) value ≤ 3 months from the initial order date (baseline), and ≥ 12 months of follow-up were identified through electronic health records. Persistent treatment was defined as no medication order gap >30 days during a 12-month period. Multivariate logistic regression was performed to assess factors associated with persistent treatment. Odds ratios (ORs) and 95% confidence intervals (CIs) were calculated. A P value \u003c.05 was considered statistically significant. RESULTS: A total of 971 patients met eligibility criteria. Forty-nine percent of patients had ≥ 12 months of persistent treatment. Multivariate analysis showed that female sex (OR = 0.69; 95% CI = 0.53, 0.90; P = .004) was associated with lesser odds of persistence, whereas baseline LDL-C at goal (1.39; 1.06, 1.82; P = .015) and concomitant use of the intestinal cholesterol absorption inhibitor ezetimibe (1.64; 1.18, 2.28; P = .003) were associated with greater odds of persistence. CONCLUSIONS: This study identified several patient demographic and characteristics associated with persistent colesevelam treatment that may help develop strategies to improve treatment persistence and optimize clinical outcomes.","description":"This study identified several patient demographic and characteristics associated with persistent colesevelam treatment that may help develop strategies to improve treatment persistence and optimize clinical outcomes.","keywords":["Cardiovascular Diseases","Disease Management","Health Services"],"datePublished":"2013-10-01","url":"https://www.sutterhealth.org/research/publications/factors-associated-with-persistent-colesevelam-tx-1055312600","inLanguage":"en-US","identifier":[{"@type":"PropertyValue","propertyID":"PMID","value":"24259687"},{"@type":"PropertyValue","propertyID":"DOI","value":"10.1177/1060028013501804"}],"sameAs":["https://pubmed.ncbi.nlm.nih.gov/24259687/","https://doi.org/10.1177/1060028013501804"],"isPartOf":{"@type":"Periodical","name":"Ann Pharmacother"},"author":[{"@type":"Person","name":"Romanelli RJ"},{"@type":"Person","name":"Leahy A"},{"@type":"Person","name":"Jukes T"},{"@type":"Person","name":"Ye X"},{"@type":"Person","name":"Kang A"},{"@type":"Person","name":"Ishisaka DY"}],"sourceOrganization":{"@type":"MedicalOrganization","name":"Palo Alto Medical Foundation Research Institute"},"about":[{"@type":"DefinedTerm","name":"Cardiovascular Diseases","url":"https://www.sutterhealth.org/research-search-results?facets=%5B%7B%22i%22%3A%22c_researchTopics.name%22%2C%22v%22%3A%5B%22Cardiovascular+Diseases%22%5D%7D%5D&verticalKey=research_publication"},{"@type":"DefinedTerm","name":"Disease Management","url":"https://www.sutterhealth.org/research-search-results?facets=%5B%7B%22i%22%3A%22c_researchTopics.name%22%2C%22v%22%3A%5B%22Disease+Management%22%5D%7D%5D&verticalKey=research_publication"},{"@type":"DefinedTerm","name":"Health Services","url":"https://www.sutterhealth.org/research-search-results?facets=%5B%7B%22i%22%3A%22c_researchTopics.name%22%2C%22v%22%3A%5B%22Health+Services%22%5D%7D%5D&verticalKey=research_publication"}],"mainEntityOfPage":{"@type":"WebPage","@id":"https://www.sutterhealth.org/research/publications/factors-associated-with-persistent-colesevelam-tx-1055312600","breadcrumb":{"@id":"https://www.sutterhealth.org/research/publications/factors-associated-with-persistent-colesevelam-tx-1055312600#breadcrumblist"}}} ```